Molecular imaging modalities are used for different type of cancers detection and diagnosis. In recent few years, there has been an increased focus on developing novel nanoparticles as new imaging contrast agents for early detection of cancer. The aim of this review article is to summarize molecular imaging technologies accompanying with using nanoparticles to improve potential imaging for cancer detection and hence valuable therapy in the future.
Introduction
At present, molecular imaging (MI) is an emerging subject that integrates advanced imaging technology with cellular and molecular biology. Molecular imaging has the strength to enhance all feature of cancer care (1) . Notable sophisticated technologies with the purpose of improving diagnostic accuracy and also individualizing treatment methods to make the most of effectiveness when reducing short-term mobility. Hence, MI is sophisticate to characterize and measure the biological process at the cellular and subcellular of living organism (2). Therefore, the mortality rate of cancer will increase significantly for earlier detection of disease, precise diagnosis of diseases and enhancing the results of treatment using appropriate imaging probes.
Molecular imaging probes can be categorized as follows: A) phenotypic probes, b) targeted probes, c) cell-tracking probes, and d) reporter gene probes. The first category is utilized to determine general features of malignant physiology, such as angiogenesis, cell proliferation, apoptosis, and the expression of certain receptors in Tumor cells. The second category is employed to images specific biomolecules which are characteristic of a Tumor or even class of Tumors. The third category is employed to localize and follow the movement of cells that may be of importance for tumor survival. The cells can be labelled directly with tags or indirectly via the insertion of marker genes. Last of all is the reporter gene probes which are used to monitor the action of genes in biologic in vivo systems (3).
Molecular imaging requires high resolution in addition to very sensitive features to detect and recognise specific imaging agents that link the imaging signal with molecular size. Molecular imaging techniques also may consider tumor characterization and cancer diagnosis without any invasive operations like biopsy or even surgery (4). Recently, there are many types of MI agents such as small molecules, peptides, aptamers, high-molecular-weight antibodies, and various nanoparticles.
Molecular imaging probes include targeting component such as antibody (5, 6), peptide (7), or small molecule and a signalling component including a radionuclide (8), fluorochrome for optical imaging (9) or a paramagnetic chelate for magnetic resonance imaging (10, 11). Nanosized probes with unique properties have emerged a potential class of MI (12).
Clinicians are using six imaging modalities to diagnose and treat the cancer. Only four of them including computed tomography (CT), magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT) and positron emission tomography (PET), are widely used for three-dimensional in cancer staging (13) . Virtually all four 3-D imaging modalities suffer from deficiencies in sensitivity as well as resolution. The ability to solve many of the most important clinical problems in terms of scale, for enhance their ability for diagnosis; they simply were not designed to image small numbers of cancer cells (14) . The aim of cancer imaging should be to detect the smallest possible number of cancer cells, before the angiogenesis. In recent years, nanoparticles have extended significant attention as contrast agents for the primary detection of cancer in current imaging system such as molecular imaging. Using nanoparticles, it is possible to (1) achieve great specificity toward a target, thus eliminating the hazard of side effects; (2) deliver a large payload quantity in a single dose and (3) simultaneously deliver both imaging agents and therapeutics.
In this review article, the current state of the art and advanced approaches in MI using nanoprobes for cancer diagnosis was considered.
Positron Emission Tomography (PET)
PET is the MI modality most extensively used in current clinic routine (15) . Its image originated from the radioactive decay of neutron-deficient or positron-enrich radioisotopes including 11 C, 15 O, 18 F, and 131 I, which they are prepared as radiopharmaceutical and intravenously injected into the body. In another word, PET modality are designed to detect the paired 511 keV photons generated from the annihilation event of a positron and electron. The paired annihilation photons travel in opposite directions (180 • apart) along a line. A PET detector surrounding the target can prepare signal and convert it into tomographic images.
Due to high sensitivity of PET, limitless depth of penetration, and quantitative capabilities, it becomes a powerful tool for clinical diagnosis and basic research including neurology, cardiology, and particularly oncology (16). In the clinical application, PET scan is essential for cancer detection and staging, in addition to evaluate the response of cancer to therapy. The main disadvantage of PET is the lack of anatomical parameters to identify molecular events with accurate correlation to anatomical findings, and this disadvantage has recently been compensated by merging these devices with either CT or MRI known as dual modalities named PET/CT and PET/MRI (17, 18). PET/CT improves the accuracy of cancer diagnosis and staging. With the widespread of instrument, it has become an important tool for predicting therapeutic response, providing useful information for the decision to stop ineffective treatment or switch to a more efficient treatment (19) .
PET/CT has changed the diagnostic algorithm in oncology by substantially influencing the management of patients with cancer (20, 21) . Among a variety of radiopharmaceuticals for molecular and metabolic imaging with PET, the most relevant biomarker for cancer remains Moreover, a novel radioligand was reported for PET which can detect the expression of uriokinase-type plasminogen activator receptors on breast cancer, urinary bladder and prostate cancer. The new radioligand was tested on patients whom diagnosed with mentioned cancers and no adverse events was found after administration and imaging by PET/CT (29 Additionally, SPECT as an excellent nuclear imaging technique which is based on detection of gamma-ray photons, utilized for imaging due to its fast detection time, specificity and more affordable compare to PET. However, SPECT is generally less sensitive and the spatial resolution of PET (5-7 mm) is higher than SPECT (8-10 mm). It was reported that, the spatial resolution of micro-SPECT that is employed in preclinical examination is higher than that of PET due to advancement of imaging tools (37) . Micro-SPECT is more accessible in preclinical examinations such as drug development in animal researches. The heavy radioisotopes such as In anti-mesothelin monoclonal antibody (Mab) targeting antigens for malignant mesothelioma, the dual-modality imaging probe was suggested for MRI/SPECT. They results showed great uptake of 111 In-MabMB-SPION and signal drop after 24 hrs post-injection.
Magnetic resonance imaging (MRI)
MR imaging is one kind of problem-solving imaging modalities for diagnostic due to its high anatomical and temporal resolution as well as contrast in soft tissue in the clinical application.
Basically, the alignment of protons from water molecules in an external magnetic field which due to magnetism property of body tissue is the basic physics of MRI. The spin of protons according to the strength of external magnetic field are affected by the radiofrequency (RF) pulse. When the RF pulse is turned off, the protons can return to the original state by transferring energy to general structure of material and generating an RF signal. The entire process is known "relaxation." After measuring the relaxation by receiver coils, the relaxations turned into an image (43) . In contrast to PET/CT, the ability of MRI to deliver functional and biological information is limited. By using MRI contrast agents to enhance the T1 and T2 relaxation rates and coupling imaging techniques such as magnetic resonance spectroscopy (MRS) may the limitation of this image modality is decreased.
During the past decades, improvement in instrument brought MRI into a new era of MI. The excellent feature of MRI as an imaging modality for MI are comparably high temporal and spatial resolution, excellent tissue contrast and tissue penetration, no ionizing radiation, noninvasiveness for serial studies, and simultaneous acquisition of anatomical structure and physiological function (44) . However, some limitation of molecular MRI is including low sensitivity, and this requires the introduction of imaging agent and development of powerful signal amplification strategies. Imaging agent design is hence an important topic in molecular MRI.
MR imaging contrast agents are mainly divided into two categories: ferromagnetism and paramagnetic. The former is considered as negative contrast agents which mainly reduce the signal in T2-weighted images, while the latter is referred to as positive contrast agents that increase the signal in T1-weighted images. The most representative negative contrast agents are superparamagnetic iron oxide (SPIO) and ultrasmall superparamagnetic iron oxide (USPIO), Gd-encapsulated silicon micro-particles, Gd-contained UCNPs and typical positive contrast agents are small molecular weight compounds involving a single Lanthanide chelate as signal producing element (5, 45, 66) .
A lot of works have been done on Gd-based contrast agents for MR imaging, which is among the world most recognized non-invasive techniques employed in clinical diagnosis of patients.
At ionic state, Gd is considered toxic but less toxic in chelate form. A variety of nano-carriers, including gadolinium oxide (Gd2O3) nanoparticles have been used by researchers to improve the T1 and T2 contrasts of MR images. Even more recently, a few researchers have tried to the use of graphene oxide (GO) and layered double hydroxides (LDH) as candidates for theranostic applications (45, 46) . True MR-based MI strategies that are clinically available include MRS. Conventional MRI is able to provide high-resolution localization of prostate tumors via their reduced T2 signal in comparison to the surrounding healthy prostate (65) . In patients with moderate and high-risk tumors, staging using the combination of MRS and MRI has been reported to be of incremental prognostic significance. Information on tumor metabolism provided by endorectal MRI/MRS may serve as a predictive marker in prostate cancer, as it can be used to identify patients with a high risk of relapse after radical prostatectomy. MRS, however, has limitations for wholebody imaging in part due to its susceptibility to respiratory and bowel motion.
Liu K et al, synthesized and applied hydrophilic CaF2:Yb,Er@CaF2:Gd nanoparticles modified using PEG-PAA di-block copolymer benefited from the presence of Gd only in the outer CaF2 layer of the nanoparticles Gd 3+ -doped CaF2-based core-shell nanoparticles for efficient magnetic resonance angiography (MRA) and tumor diagnosis (66) .
Gd-based bovine serum albumin (BSA) hybrid-coated hollow gold nanoshells (Au@BSA-Gd) was applied for nanotheranostic agent due to its hollow and porous structures, hence possessing photodynamic/photothermal property and near-infrared fluorescence (NIRF)/PA and excellent T1 contrast agent for MRI capability as shown in Fig. 1 (67) . A multimodal contrast agents for integrated preoperative MRI and intraoperative fluorescence image-guided surgery (FIGS) was performed by Payne et al., (68) in which self-assembled multimodal imaging nanoparticles (SAMINs) were developed as a mixed micelle formulation using amphiphilic HA polymers functionalized with either Gd-DTPA for T1-weighted MRI.
They employed simulated surgical phantoms that are routinely used to evaluate the depth at which near infrared (NIR) imaging agents can be detected by FIGS. Studied nanoprobe imaging agent efficacy was also evaluated in a human breast tumor xenograft model in nude mice. showed potential CT contrast in both in vivo and in vitro studies (88) . Additionally, it was reported elsewhere that Au PSNPs (methyl-orange-doped polystyrene gold nanoparticle) not only confirmed as CT contrast agent also it suggested to utilize for blood pool imaging (89).
Computed Tomography (CT)
The slight difference in the size of AuNPs after modification is due to either specific localization of gold nanoparticle in targeted Tumor (90) 
Ultrasound molecular imaging
Compared with other MI modalities, ultrasound imaging has many advantages including good temporal resolution, qualitative data, real-time practice, non-invasiveness, relatively inexpensive coast, and no ionizing radiation. In addition, it is a unique modality in some sense that it can be employed for diagnostic imaging and as a therapeutic tool. One type of contrast agent that applied in ultrasound (US) modality is Microbubble (MB). MB enhanced the specificity and sensitivity of cancer detection. However, micro meter range size of MB is an obstacle for extravasation from the vasculature. Therefore, only intravascular targets are potentially obtained. Besides, the reduction of unspecific background signals is observed by molecular US imaging. It is worth to mention that, many intravascular targets significantly diagnose inflammation and characterize angiogenesis (102).
Common targets for molecular ultrasound imaging are surface receptor molecules expressed on the luminal side of activated endothelium, either in response to inflammatory or to angiogenic stimuli. Angiogenesis, the process of new blood vessels formation, plays the main role of tumor neovascularisation. Neo-angiogenesis is the initiation of Tumors which can be predicator of spreading cancer cells to other organs. Angiogenesis needs oxygen and other nutrients to remove useless cellular residues. US is able to expose flow dynamic of vessels less than 500 micrometres which is greater than angiogenic capillaries by using targeted microbubbles.
A study in cellular and molecular biology suggested identifying new angiogenic biomarkers and their molecular signalling path ways with the use of US contrast agent, US imaging enables specific and sensitive depiction of molecular targets (103) .
Compared with other MI modalities, ultrasound MI has many advantages including good temporal resolution, quantitative data, real-time practice, non-invasiveness, relatively inexpensive cost, and no ionizing radiation. In addition, it is a unique modality in some sense that it can be employed for diagnostic imaging and as a therapeutic tool (104). Martins et al. 
Optical imaging
Optical imaging is a non-invasive modality for looking inside the body, which uses visible light and the special properties of photons, infrared, and ultraviolet to obtain detailed images of organs and small structures like cells and molecules. These images are used by scientists for research and by clinicians for diagnosis and treatment of abnormalities, in particular cancers.
In fact, by applying this modality, various colors of light are using to visualize and to measure various properties of a specific organ or tissue target. Moreover, combination of mentioned technique with other modality such as MRI, CT or X-ray, can enhance the information of disease. 
Conclusions
In this review, a broad overview of nanoparticles applications in molecular imaging modalities was provided for cancer detection. These modalities are of great importance in diagnosing of cancer at early stages. This review article could useful from point of tutorial and educational view for all medical students and nanotechnology researchers who are interested in cancer imaging and therapeutic. The limitation of this article is that have not covered every aspect of all imaging modalities for cancer detection in details.
With knowledge of the correlation between the application of nanoparticles and molecular imaging modalities and with the development of targeted contrast agents or nanoprobes, they may provide better cancer diagnosis in the future. Dudczak R, Traub-Weidinger T. PET and PET/CT in endocrine Tumors. 
